Praxis Precision Medicines (PRAX) Set to Announce Earnings on Wednesday

Praxis Precision Medicines (NASDAQ:PRAX) is scheduled to post its quarterly earnings results before the market opens on Wednesday, November 6th. Analysts expect Praxis Precision Medicines to post earnings of ($2.01) per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

Praxis Precision Medicines (NASDAQ:PRAX) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($1.74) EPS for the quarter, topping the consensus estimate of ($2.38) by $0.64. Praxis Precision Medicines had a negative net margin of 6,987.01% and a negative return on equity of 61.47%. The business had revenue of $0.36 million during the quarter, compared to analysts’ expectations of $1.44 million. On average, analysts expect Praxis Precision Medicines to post $-9 EPS for the current fiscal year and $-9 EPS for the next fiscal year.

Praxis Precision Medicines Stock Performance

Shares of PRAX opened at $65.00 on Monday. The company has a market capitalization of $1.15 billion, a PE ratio of -6.67 and a beta of 2.67. The company’s 50 day moving average price is $62.58 and its 200 day moving average price is $53.25. Praxis Precision Medicines has a 52 week low of $13.01 and a 52 week high of $75.73.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Needham & Company LLC restated a “buy” rating and set a $145.00 price target on shares of Praxis Precision Medicines in a report on Tuesday, September 3rd. Guggenheim upped their target price on Praxis Precision Medicines from $155.00 to $170.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. HC Wainwright reiterated a “buy” rating and set a $120.00 price target on shares of Praxis Precision Medicines in a report on Tuesday, September 10th. Wedbush increased their price objective on Praxis Precision Medicines from $40.00 to $48.00 and gave the stock a “neutral” rating in a report on Wednesday, August 14th. Finally, Oppenheimer lifted their target price on shares of Praxis Precision Medicines from $143.00 to $163.00 and gave the company an “outperform” rating in a research note on Thursday. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $145.67.

Praxis Precision Medicines Company Profile

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.